Interchangeability study for HADLIMA (adalimumab-bwwd) was conducted in accordance with the FDA’s Guidance for Industry; primary pharmacokinetics (PK) endpoints as...
WOBURN, MA / ACCESSWIRE / March 8, 2024 / Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of...
VANCOUVER, BC, March 8, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the "Company") today announced...
CLARKSBURG, MD / ACCESSWIRE / March 7, 2024 / The American Society for Colposcopy and Cervical Pathology (ASCCP) is proud...
PITTSBURGH, March 7, 2024 /PRNewswire/ -- eHealth Technologies, a trailblazer in healthcare technology solutions for close to 20 years, has...
Clinical-stage CAR-T company is actively recruiting patients to evaluate SynKIR™-110, a new treatment candidate for ovarian cancer, mesothelioma, and cholangiocarcinoma...
Conference call and webcast: today, March 7, 2024, 9:00 am E.T. +1-888-407-2553 or +972-3- 9180608 I https://veidan.activetrail.biz/evogeneq4-2023 REHOVOT, Israel, March...
PROVIDENCE, R.I., March 7, 2024 /PRNewswire/ -- Next generation genomic tools company, Nabsys®, has executed a nonexclusive agreement with Canadian distributor,...
API advancements and new technology partnerships will be highlighted in MEDITECH Interoperability Showcase Kiosk #71CANTON, Mass.--(BUSINESS WIRE)--As the healthcare industry...
Initial interim data show favorable drug exposure and confirm ALG.APV-527 biological activityEarly promising signs of clinical activity in heavily pretreated...
NORTHAMPTON, MA / ACCESSWIRE / March 7, 2024 / Gilead SciencesFor many people living with cancer, hearing about the experiences...
PARIS, March 07, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that the first commercial...
AIM CEO Corner AIM CEO Corner CEO Corner segments to provide added perspective to press releases, corporate developments and pipeline...
BOSTON and ATLANTA, March 07, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical...
Company announces new partners including The University of Texas and Rising Pharmaceuticals FREDERICK, Md., March 07, 2024 (GLOBE NEWSWIRE) --...
Data support evaluation of the effects of two weeks of TNX-102 SL therapy on severity of acute stress reaction (ASR)...
Agreement with a leading cancer treatment group to advance the clinical development of Bria-OTS+ (breast cancer) and Bria-PROS+ (prostate cancer),...
Company maintains solid cash position of $158.9 millionSOUTH SAN FRANCISCO, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc....
Five abstracts accepted for poster presentation highlight Company’s proprietary Conditionally Active Biologic (CAB) technologyDifferentiated preclinical activity for CAB anti-Nectin4-antibody drug...
Bionano will host a pre-conference scientific session that will include a live product demonstration of the Stratys™ system for high...